Mutations in RHPN2 (5%), GLI3 (4%) and MRC2 (2%) have not been reported previously as driver genes in lung adenocarcinomas but were recurrently observed in our cohort and are nominated to be significantly mutated. Here, MRC2 is linked to lung adenocarcinoma.